Update: ACIP 2024 Adult Immunization Recommendations
This summary of updates to the ACIP 2024 Adult Vaccination recommendations includes 4 new vaccines and new formulations for COVID-19 and influenza shots.
Adult immunizations recommended by the Advisory Committee on Immunization Practices of the CDC.
4 new vaccines on the ACIP 2024 adult immunization schedule.
RSV vaccination for older adults updated recommendations from the ACIP.
Mpox vaccine: Risk factors for eligibility
Meningococcal vaccination recommendations now include the pentavalent MenABCWY from Pfizer.
The COVID-19 vaccine formulation for the 2024-2025 respiratory virus season has been modified; the antigen will be a monovalent JN.1 lineage.
The updated 2024-2025 influenza vaccine will be a trivalent formulation with protection against an H1N1, H3N2 and a B/Victoria lineage virus.
Polio vaccination guidance for adults has been updated.
Hepatitis B vaccination for adults aged >60 years - risk based guidance has been updated.
21-valent pneumococcal vaccine now available and recommended for all adults aged ≥65 yrs who have not received a PCV or whose history is unknown.
Which pneumococcal vaccine is recommended for adults aged ≥65 years and when should it be administered?
Which pneumococcal vaccine when for adults aged ≥65 years …
Progress toward a pandemic influenza vaccine--p.reparing for the possible.
This summary of the Advisory Committee on Immunization Practices 2024 Adult Immunization Schedule,1 approved and released by the Centers for Disease Control and Prevention in January 2024, highlights 4 new vaccines, new recommendations,2 and subsequent developments that include new COVID-19 vaccine targeted strain and updated RSV vaccine recommendations.
